Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Zydus Cadila unveils...

    Zydus Cadila unveils affordable anti-diabetic drug Vildagliptin under brands Vinglyn, Vinglyn M

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-12-12T11:53:19+05:30  |  Updated On 15 Dec 2023 12:14 PM IST
    Zydus Cadila unveils affordable anti-diabetic drug Vildagliptin under brands Vinglyn, Vinglyn M

    Ahmedabad: With the Novartis Blockbuster Vildagliptin going off patent, Zydus Cadila has taken made its move towards affordable diabetes care in India with the launch of its oral anti-diabetic agents under the brand name Vinglyn (Vildagliptin) & Vinglyn M (Vildagliptin plus metformin). Priced at 1/6 the price of the earlier patented drug, the new drugs are indeed going to lighten the pockets of patients aiming at blood sugar control and diabetes management.


    Read also: Vildagliptin, Metformin combo shows long term blood sugar control in newly diagnosed diabetics

    Diabetes has a high prevalence in Indian, with approximately 12% of male and 11.7% of female adults being impacted by the disease.

    Commenting on the launch, Dr Sharvil Patel, Managing Director, Zydus Cadila, said, "Diabetes is becoming a major health burden globally. Fortifying our fight against diabetes, our aim is to make therapies affordable and accessible to patients from across sections of society. With Vinglyn, we believe that we have once again been able to offer this. Access to one of the most affordable gliptin therapies will help a large number of patients suffering from Type II diabetes, in India.”

    Vildagliptin belongs to the class of anti-diabetic medications called DPP-4 inhibitor or gliptins. The drug is prescribed as a once-daily drug and may often be combined with another anti-diabetic drug metformin. Apart from Vildagliptin, there are other gliptins like Sitagliptin, Saxagliptin and Teneligliptin. However, Vildagliptin has about 25% share of the gliptins market of Rs 3500 crore.


    The recent launch of Vinglyn (Vildagliptin) & Vinglyn M (Vildagliptin plus metformin) by Zydus is indeed a reason for diabetics to rejoice as the incidence of diabetes. With a patient population of almost 77 million diabetics in India, access to affordable therapy is vital for the effective management of the disease.


    DPP4 inhibitors have shown promise in achieving glycaemic control without deterioration in beta-cell function and are one of the recent advancements in diabetes care and management.


    Cheaper Version of Vildagliptin


    Priced at just Rs 4.95 per tablet, which is almost 1/6th the price at which the patented Vildagliptin was initially launched in India, Vinglyn is now one of the most affordable brands of Vildagliptin for diabetic patients in India. Earlier, the price of each tablet of Vildagliptin ranged between Rs 20 to Rs 28.


    Read Also: With Vildagliptin off-patent from today, new doors open for pharma players


    Further, the diabetes therapy market is witnessing a number of pharma players cashing in on Vildagliptin with Zydus Cadila being one of the initial firms to launch and market the drug under trade name Vinglyn and Vinglyn M.


    Read Also: Zydus Cadila gets tentative USFDA nod for Lorcaserin Hydrochloride Tablets to treat obesity

    antidiabetic tabletsblood sugar medicineCadilacheaper vildagliptindiabetesdiabetes drugHealthcareNovartispharmapharma companypharma newsVildagliptinVinglynVinglyn MZydus Cadila
    Source : from the industry

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok